2021

1. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

   The Lancet Respiratory Medicine, Vol. 9, Núm. 3, pp. 260-274

2. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

   BMC Pulmonary Medicine, Vol. 21, Núm. 1